24 results
425
ONCT
Oncternal Therapeutics Inc
24 May 19
Business combination disclosure
5:12pm
& Severance
General and Administrative
SARD Development
Other R&D(1)
Total R&D
Total Cash Expense
Gross Cash Balance
Net Cash Balance(2)
(1) Consists … Expenses
Salaries, Benefits & Severance
General and Administrative
SARD Development
Other R&D(1)
Total R&D
Total Cash Expense
Gross Cash Balance
Net
8-K
ONCT
Oncternal Therapeutics Inc
24 May 19
Other Events
5:14pm
& Severance
General and Administrative
SARD Development
Other R&D(1)
Total R&D
Total Cash Expense
Gross Cash Balance
Net Cash Balance(2)
(1) Consists … Expenses
Salaries, Benefits & Severance
General and Administrative
SARD Development
Other R&D(1)
Total R&D
Total Cash Expense
Gross Cash Balance
Net
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
23 Mar 10
GTx and Ipsen expand partnership
12:00am
& Development (R&D) centers and peptide & protein engineering platform give the Group a competitive edge. Almost 900 people are dedicated to the discovery … and development of innovative drugs for patient care. In 2009, R&D spend reached close to €200 million, representing more than 19% of total Group sales
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
7 Sep 06
Regulation FD Disclosure
12:00am
by an active policy of partnerships. The location of its four R&D centers (Paris, Boston, Barcelona and London) gives the Group a competitive edge in gaining … . 20.9% of consolidated sales, which amounted to EUR 807 million in the Group’s pro forma accounts set up according to the IFRS. Nearly 700 people in R
8-K
EX-99.1
zoffo65q1el6z0t4v
4 Nov 21
Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
4:01pm
8-K
EX-1.1
o3v35v6 xzm8zkxpc
14 Dec 06
Entry into a Material Definitive Agreement
12:00am
8-K
EX-1.1
kvcilmnhre
27 Oct 10
GTx Announces Pricing of Public Offering of Common Stock
12:00am